文献速递白血病造血干细胞移植与细胞治疗

含全人源scFv的CD19 CAR T细胞疗法在未接受过CAR治疗的成人B细胞急性淋巴细胞白血病中的1期研究

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.
PubMed 文献 · Blood Adv · 2025-01-01

这项1期临床试验纳入23例复发或难治性B细胞急性淋巴细胞白血病成人患者,接受淋巴细胞清除化疗后输注含全人源scFv的CD19 CAR T细胞(JCAR021)。总体缓解率82%,完全缓解/不完全血液学恢复的完全缓解率64%,中位缓解持续时间10个月,4年缓解概率29%。

要点

  • 19例(83%)发生细胞因子释放综合征,其中2级占61%;12例(52%)发生神经毒性,≥3级占35%。
  • 总体缓解率82%,完全缓解/不完全血液学恢复的完全缓解率64%。
  • 中位缓解持续时间10个月,4年缓解概率29%;低骨髓疾病负荷者观察到持久缓解。

核心结论

  • 含全人源scFv的CD19 CAR T细胞(JCAR021)在未接受过CAR治疗的复发或难治性B细胞急性淋巴细胞白血病成人中产生与含鼠源scFv的CAR相似的结局。
  • 低骨髓疾病负荷患者观察到持久缓解,而高骨髓负荷患者缓解持续时间有限。

研究设计与样本

  • 1期临床试验(NCT03103971),23例复发或难治性B细胞急性淋巴细胞白血病成人患者接受淋巴细胞清除化疗和JCAR021输注。

主要发现

  • 19例(83%)发生细胞因子释放综合征(任何级别),其中2级占61%;12例(52%)发生神经毒性,≥3级占35%。
  • 总体缓解率和完全缓解/不完全血液学恢复的完全缓解率分别为82%和64%。
  • 在有骨髓疾病的患者中,82%达到可测量残留病阴性的骨髓缓解;在有可测量氟脱氧葡萄糖亲和性疾病的患者中,79%达到正电子发射断层扫描-计算机断层扫描的髓外缓解(完全缓解50%)。
  • 中位缓解持续时间为10个月,4年缓解概率为29%。
  • 4例患者在JCAR021后达到完全缓解/不完全血液学恢复的完全缓解期间接受异基因造血细胞移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed chimeric antigen receptor-engineered (CAR) T-cell therapy elicits high response rates but fails to induce durable responses in most adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In a previous clinical trial, we observed anti-CAR immune responses associated with impaired in vivo CAR T-cell expansion after second infusions. Because these CD8+ T-cell responses were predominantly directed at peptides derived from the murine single-chain variable fragment (scFv) in the CAR, we conducted a clinical trial investigating the safety and efficacy of CD19 CAR T-cells engineered with a CAR incorporating a fully human scFv (JCAR021) in adults with R/R B-ALL (NCT03103971). Twenty-three patients received lymphodepletion chemotherapy and JCAR021 infusion. Nineteen patients developed cytokine release syndrome (any grade, 83%; grade 2, 61%) and 12 developed neurotoxicity (52%; grade ≥3, 35%). The overall response and complete response (CR)/CR with incomplete hematologic recovery (CRi) rates were 82% and 64%, respectively. We observed measurable residual disease-negative bone marrow (BM) responses in 82% of those with BM disease and extramedullary responses by positron emission tomography-computed tomography in 79% (CR, 50%) of those with measurable fluorodeoxyglucose-avid disease. The median duration of remission (DOR) was 10 months with a 4-year DOR probability of 29%. Four patients underwent allogeneic hematopoietic cell transplantation while in CR/CRi after JCAR021. Durable remissions were observed in patients with low BM disease burden. In contrast, the DOR was limited in those with high BM burden. We observed similar outcomes in CAR-naïve adult patients with B-ALL receiving CD19 CAR T cells expressing a fully human or murine scFv-containing CAR. This trial was registered at www.ClinicalTrials.gov as #NCT03103971.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gauthier J, Liang EC, Huang JJ, et al. Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL. Blood Adv. 2025. PMID: 39820359. doi:10.1182/bloodadvances.2024015314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。